These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 17414226)

  • 41. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
    Das S; Armstrong J; Mathews D; Li J; Edeki T
    J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.
    Khalilieh SG; Yee KL; Fan L; Liu R; Heber W; Dunzo E; Triantafyllou I; Hussaini A; Iwamoto M
    Clin Drug Investig; 2017 Oct; 37(10):975-984. PubMed ID: 28785879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
    Malik M; van Gelderen EM; Lee JH; Kowalski DL; Yen M; Goldwater R; Mujais SK; Schaddelee MP; de Koning P; Kaibara A; Moy SS; Keirns JJ
    Clin Pharmacol Ther; 2012 Dec; 92(6):696-706. PubMed ID: 23149929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
    Noel GJ; Natarajan J; Chien S; Hunt TL; Goodman DB; Abels R
    Clin Pharmacol Ther; 2003 Apr; 73(4):292-303. PubMed ID: 12709719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study.
    Damle B; Fosser C; Ito K; Tran A; Clax P; Uderman H; Glue P
    J Clin Pharmacol; 2009 Mar; 49(3):291-300. PubMed ID: 19246729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study.
    Green CL; Whellan DJ; Lambe L; Bellibas SE; Wijngaard P; Prats J; Krucoff MW
    J Cardiovasc Pharmacol; 2013 Nov; 62(5):466-78. PubMed ID: 23921301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.
    Matthys G; Park JW; McGuire S; Wire MB; Zhang J; Bowen C; Williams D; Jenkins JM; Peng B
    Br J Clin Pharmacol; 2010 Jul; 70(1):24-33. PubMed ID: 20642544
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
    Kubitza D; Mueck W; Becka M
    Drug Saf; 2008; 31(1):67-77. PubMed ID: 18095747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis.
    Tyl B; Kabbaj M; Azzam S; Sologuren A; Valiente R; Reinbolt E; Roupe K; Blanco N; Wheeler W
    J Clin Pharmacol; 2012 Jun; 52(6):893-903. PubMed ID: 21642470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
    Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
    Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of effect of reboxetine on cardiac repolarization.
    Fleishaker JC; Francom SF; Herman BD; Knuth DW; Azie NE
    Clin Pharmacol Ther; 2001 Sep; 70(3):261-9. PubMed ID: 11557914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants.
    Zhang X; Jordan P; Cristea L; Salgo M; Farha R; Kolis S; Lee LS
    J Clin Pharmacol; 2012 Apr; 52(4):520-9. PubMed ID: 21558456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.
    Boni JP; Leister C; Hug B; Burns J; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1433-42. PubMed ID: 22367193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of milnacipran on cardiac repolarization in healthy participants.
    Periclou A; Palmer RH; Zheng H; Lindamood C
    J Clin Pharmacol; 2010 Apr; 50(4):422-33. PubMed ID: 20103694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval.
    Beasley CM; Mitchell MI; Dmitrienko AA; Emmick JT; Shen W; Costigan TM; Bedding AW; Turik MA; Bakhtyari A; Warner MR; Ruskin JN; Cantilena LR; Kloner RA
    J Am Coll Cardiol; 2005 Aug; 46(4):678-87. PubMed ID: 16098435
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
    Harvey AT; Flockhart D; Gorski JC; Greenblatt DJ; Burke M; Werder S; Preskorn SH
    J Clin Pharmacol; 2004 Oct; 44(10):1173-84. PubMed ID: 15342619
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
    Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
    J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study.
    Hulhoven R; Rosillon D; Letiexhe M; Meeus MA; Daoust A; Stockis A
    Eur J Clin Pharmacol; 2007 Nov; 63(11):1011-7. PubMed ID: 17891537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.